Swedish Orphan Biovitrum AB (BIOVF)

28.62 0.00 (0.00%) USD  |  OTCM  |  Dec 13, 16:00
More

Swedish Orphan Biovitrum Max Drawdown (5Y): 51.25% for Nov. 30, 2024

Max Drawdown (5Y) Chart

View Max Drawdown (5Y) for BIOVF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cumulative Total Returns Versus Peers
Start Trial

Historical Data

View Historical Data
Start Trial

Max Drawdown Definition

View Max Drawdown Definition
Start Trial

Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.

Read full definition.

Max Drawdown (5Y) Range, Past 5 Years

View Max Drawdown (5Y) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Max Drawdown (5Y) Benchmarks

View Max Drawdown (5Y) Benchmarks
Start Trial
Abliva AB 99.34%
Oncopeptides AB --
BioInvent International AB 62.75%
Hansa Biopharma AB 92.88%
BioArctic AB --

Max Drawdown (5Y) Related Metrics

Alpha (5Y) 1.282
Beta (5Y) 0.5126
Annualized Standard Deviation of Monthly Returns (5Y Lookback) 41.48%
Historical Sharpe Ratio (5Y) 0.196
Historical Sortino (5Y) 0.324
Monthly Value at Risk (VaR) 5% (5Y Lookback) 17.29%